NYMALIZE (Nimodipine) Patent Expiration, LOE Window & CMS Spending
NYMALIZE (Nimodipine) by Azurity: FDA Orange Book core substance LOE 2038-04-16, 1 AB generics, $0 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Azurity |
| FDA Application & Pathway | N203340 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-04-16 |
| Last Listed Patent or Exclusivity Date | 2038-04-16 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 9 WAC filings (max 26.4% 2-yr change) |